

22 **Abstract**

23 The opioid epidemic may impact the HIV-1 reservoir and its reversal from latency in virally 24 suppressed people with HIV (PWH). We studied forty-seven PWH and observed that lowering 25 the concentration of HIV-1 latency reversal agents (LRA), used in combination with small 26 molecules that do not reverse latency, synergistically increases the magnitude of HIV-1 re-27 activation *ex vivo*, regardless of opioid use. This LRA boosting, which combines a Smac mimetic 28 or low-dose protein kinase C agonist with histone deacetylase inhibitors, can generate 29 significantly more unspliced HIV-1 transcription than phorbol 12-myristate 13-acetate (PMA) 30 with ionomycin (PMAi), the maximal known HIV-1 reactivator. LRA boosting associated with 31 greater histone acetylation in $CD4^+$ T cells and modulated T cell activation-induced markers and 32 intracellular cytokine production; Smac mimetic-based boosting was less likely to induce 33 immune activation. We found that HIV-1 reservoirs in PWH contain unspliced and 34 polyadenylated (polyA) virus mRNA, the ratios of which are greater in resting than total $CD4^+$ T 35 cells and can correct to 1:1 with PMAi exposure. Latency reversal results in greater fold-change 36 increases to HIV-1 poly(A) mRNA than unspliced message. Multiply spliced HIV-1 transcripts 37 and virion production did not consistently increase with LRA boosting, suggesting the presence 38 of a persistent post-transcriptional block. LRA boosting can be leveraged to probe the 39 mechanisms of an effective cellular HIV-1 latency reversal program. 40 41 42

- 43
- 44

45 **Introduction**

61 reported under some conditions to synergistically increase HIV-1 transcription in $CD4^+$ T cells

62 isolated from virally suppressed participants with HIV (28-32). Generally, the sample sizes were

63 small and evaluated LRA concentrations in the mid-nanomolar to micromolar range. The

64 absolute amount of HIV-1 latency reversal reported with combination LRA, defined primarily as 65 induced levels of HIV-1 caRNA, has been significantly less than that observed with the maximal

66 HIV-1 reactivating combination of phorbol 12-myristate 13-acetate (PMA) and ionomycin

and the state of th

67 (PMAi). A trade-off may exist between maximum synergy and maximum efficacy in 68 combination LRA approaches (33).

69 While HIV-1 is generally accepted to be transcriptionally silent during suppressive ART, 70 this latency may not be absolute. Studies demonstrate that short promoter proximal transcripts of 71 less than 60 nucleotides may be generated in the absence of the HIV-1 trans-activator of transcription protein, Tat $(34, 35)$. More recently, resting CD4⁺ T cells isolated from PWH were 73 found to contain transcripts extending beyond the transcriptional pausing site, a minority of 74 which may be full-length or spliced and polyadenylated (36). Total $CD4^+$ T cells isolated from 75 PWH may contain approximately sevenfold more proximal HIV-1 transcripts, of at least 185 76 nucleotides in length, than polyadenylated virus mRNA (23). HIV-1 cell-associated RNA is 77 readily detectable in the blood and tissue of PWH on virologically suppressive ART (37-40). 78 People with HIV may be exposed to opioids, whether prescribed for chronic pain (41), 79 prescribed for opioid use disorder (42), or injected as heroin (43). The pharmacology of opioids 80 associated with substance use disorders may differ from opioid medications used to treat chronic 81 pain. The µ opioid agonists, e.g. heroin, fentanyl, morphine, and methadone, can block IL-2 82 mRNA and protein production in activated T cells through inhibition of AP-1, NFAT, and NF-83 KB activation, transcription factors known to be positive regulators of HIV transcription 84 initiation (44-46). The effects of buprenorphine, a partial µ opioid agonist and κ and δ opioid 85 antagonist commonly used in the treatment of opioid use disorder, on HIV-1 latency and its 86 reversal have not been explored. A recent finding suggested that people with HIV who use 87 opioids may have diminished responses to latency reversal mediated by T cell receptor (TCR) 88 agonism (47).

and the control of t
And the control of t

109

110 **Results**

111 **Opioid use does not affect HIV-1 reservoir size**

112 We enrolled the Opioids, HIV, and Translation (OPHION) cohort from a single academic 113 center of thirty-six virally suppressed participants with HIV who used, or did not use, opioids in 114 a 2:1 ratio. Participants had a median age of 59 years, included one-third women, and were 115 approximately 30% white (**Table 1**). The median duration of ART was 12 years with a median 116 duration of undetectable plasma HIV-1 RNA levels of over six years. Participant characteristics 117 were further defined by type of opioid use (**Suppl. Table 1**) and validated by urine toxicology 118 and self-reported substance use questionnaires (**Suppl. Fig. 1**). To reflect the range of opioid use 119 encountered in clinical practice, this cohort comprised participants who actively injected opioids 120 (n=4), used methadone (n=4) or suboxone (n=12) as medication for opioid use disorder, or took 121 opioids for chronic pain (n=4). Amphetamine and barbiturate use were not detected. All active 122 injection opioid users had confirmatory urine toxicology screens positive for fentanyl (n=2 of 4, 123 range 62 - >500 ng/mL) and/or norfentanyl (n=4 of 4 participants, range 46 - >500 ng/mL) and 124 reported a median of 6 days of injection opioid use in the preceding 30 days (IQR 4-16 days) 125 with a median of 7 days since the most recent use (IQR 4-14 days). All participants in the 126 methadone, buprenorphine, and prescription opioid subgroups had urine toxicology positive for 127 that substance.

128 To assess markers of HIV-1 persistence, we quantified total HIV-1 DNA and caRNA in 129 PBMC and evaluated intact proviral reservoir size (**Fig. 1**). Total HIV-1 DNA levels were statistically similar between opioid and non-opioid groups, 2.36 vs 2.38 log_{10} copies/10⁶ PBMC, respectively, as were HIV-1 caRNA levels, 2.45 vs $2.52 \log_{10} \text{copies}/10^6 \text{ PBMC}$ (Fig. 1a). 132 Levels of intact provirus DNA were also similar between groups, 2.00 vs 1.82 log_{10} copies/10⁶

65 August 2014

133 **Table 1. OPHION Participant Characteristics**

^{*}Percentage totals may not add up to 100 due to rounding. [†]IQR, interquartile range. ^{**}Participants may

135 identify as Hispanic/Latino either in response to a question about their race, or a follow-up question on

136 ethnicity. Participants who reported Hispanic ethnicity identified their race as either "White" or

137 "Declined/Not Available."

138

139

140

149 **LRA boosting markedly increases HIV-1 transcription**

150 To determine the effects of opioid use on HIV-1 latency reversal *ex vivo*, we isolated 151 PBMC from thirty-six participants enrolled in the OPHION cohort and tested a panel of ten LRA 152 conditions (**Fig. 2**). The histone deacetylase inhibitors (HDACi) romidepsin (RMD) and 153 panobinostat (PNB) were used at the lowest concentrations most commonly reported in the 154 literature and the protein kinase C agonist bryostatin was tested at 1nM, one-tenth the most 155 commonly reported concentration. In single LRA conditions, we observed a 2.7-fold activation 156 of HIV-1 caRNA transcription, relative to an untreated DMSO-containing control, with anti-157 CD3/anti-CD28 (αCD3/αCD28) beads, a T cell receptor (TCR) agonist (**Fig. 2a**). This 158 magnitude of TCR agonism-induced latency reversal is consistent with prior studies (23, 48-52). 159 Statistically greater reactivation was observed with RMD (3.8-fold increase) when compared to 160 PNB (2.6-fold increase) (**Suppl File 1**). Low-dose bryostatin minimally increased unspliced 161 HIV-1 caRNA levels (1.2-fold increase), but the Smac mimetic AZD5582 (AZD), at a standard 162 concentration (53), did not (0.9-fold increase, 95% CI [0.8, 1.1]).

and the state of th

181 assays (**Suppl. Fig. 3, Fig. 3a**), originally developed to detect T cell antigen responsiveness, to

182 quantify cellular activation that occurs with LRA exposure, outside the context of peptide-

- 183 specific recognition. Using TCR agonism as a positive control, responses were detected in 49%,
- 184 32%, and 42% of CD4⁺ T cells in the OX40/PDL1, OX40/CD25, and CD69/CD40L AIM assays,
- 185 respectively (**Fig. 3b**). Low-dose bryostatin significantly upregulated surface expression to more

e de la construcción de la construcción
En la construcción de la const

100 million and the contract of the contract o

224

225 **LRA boosting increases histone acetylation**

226 To investigate the mechanism(s) of LRA boosting, we next assessed histone acetylation. 227 The proportions of acetylated histone $H3^+$ live CD4s were similar between untreated cells 228 (19.7%) and cells exposed to RMD (21.8%), PNB (21.7%), or AZD (19.8%) and significantly 229 increased after single-LRA exposure to α CD3/ α CD28 beads (35.5%) and low-dose bryostatin 230 (29.2%) (**Fig. 4a**). Low-dose bryostatin in combination with either RMD (36.8%) or PNB 231 (37.5%) significantly increased the proportions of CD4s contained acetylated histone H3.

111 - Andrew Marie Barbara, Amerikaansk politiker
1111 - Johann Sterlin, Amerikaansk po

232 Interestingly, statistically significant increases in the proportions of acetylated histone $H3$ ⁺ live 233 CD4s were also observed when combining LRA which individually did not affect these 234 percentages, specifically $RMD + AZD (30.0%)$ and $PNB + AZD (29.8%).$ These results did not 235 differ by opioid use (**Suppl. Fig 5a**). 236 Levels of acetylated histone H3, measured by median fluorescence intensity (MFI), were 237 similar in untreated live CD4s and in cells cultured with α CD3/ α CD28 beads, low-dose 238 bryostatin, or AZD (**Fig. 4b**). Significant 3.4-fold and 3.3-fold increases in acetyl histone MFI 239 were observed for RMD and PNB, respectively. AZD in combination with RMD or PNB further 240 increased MFI by 6.1- fold and 5.7-fold, respectively. Absolute increases in MFI were observed 241 for low-dose bryostatin in combination with RMD or PNB but did not retain significance after 242 correction for multiple comparisons. These results did not differ by opioid use (**Suppl. Fig 5b**). 243 We observed no association between acetylated histone H3 MFI and fold-change in HIV-1 RNA 244 levels for HDACi monotherapy or for HDACi in combination with AZD (**Fig 4c-d**). A 245 statistically significant weak association between the proportion of acetyl histone $H3^+$ CD4s and 246 fold-change in HIV-1 RNA levels was detected for HDACi in combination with bryostatin (**Fig** 247 **4e**). 248 249 **LRA boosting does not consistently induce virion production** 250 To extend our analyses from the OPHION cohort, we next studied an additional eleven

251 participants with HIV who did not use opioids, enrolled in the HEAL cohort, for whom 252 leukapheresis samples were available (**Supplementary Table 2**). We compared LRA boosting 253 responses in PBMC to the most potent known HIV-1 LRA, PMA in combination with ionomycin 254 (PMAi). Significant fold-change increases in HIV-1 transcription were observed with

12 - Paul III, amerikansk politiker (* 1200)
12 - Jan Bartha, fransk politiker (* 1200)
12 - Jan Bartha, fransk politiker (* 1200)

13

278 95% CI [14, 43]), and PNB plus bryostatin (35 copies/mL, 95% CI [19, 60]) or AZD (12 279 copies/mL, 95% CI [8.1, 26]), when compared to untreated PBMC (3.0 copies/mL, 95% CI [2.2, 280 6.9]), but these results were not statistically significant after correction for multiple comparisons 281 (**Fig. 5e**). This virion production response was dichotomized by participant. For each LRA 282 condition, PBMC samples from at least 5 of 10 participants showed no increases in HIV-1 RNA 283 levels over control; these were most commonly the same participants. Additionally, no significant increases in LRA-induced virion production in isolated $CD4^+$ T cell cultures were 285 observed. Greater virion production in untreated CD4s and greater absolute magnitudes of LRA-286 associated supernatant viremia in CD4s were noted, relative to PBMC, but these increases were 287 seen in only a subset of participants. To define this post-transcriptional block more precisely, we 288 quantified the frequency of CD4s with inducible multiply spliced HIV-1 RNA transcripts (**Fig.** 289 **5f**) (56). No significant increases in the frequency of cells that contain HIV-1 *tat*/*rev* transcripts 290 were observed with RMD in combination with bryostatin at either 1nM or 10nM concentrations. 291 In a post-hoc analysis, we combined datasets from OPHION and HEAL participants, including 292 LRA conditions common to both sets of experiments, and observed statistically significant 293 increases in HIV-1 unspliced RNA transcription with all LRA boosting combinations (**Fig. 5g,** 294 **Suppl. Fig 7b**). The variance in LRA response, defined by the interquartile range, increased as 295 the magnitude of fold change in HIV-1 caRNA increased.

296

297 **Effective latency reversal normalizes unspliced:polyadenylated HIV-1 mRNA ratios**

298 We observed lower PMAi-associated fold-changes in HIV-1 caRNA levels with our unspliced 299 HIV-1 RNA qPCR assay when compared to prior studies that quantified poly-adenylated 300 (poly(A)) HIV-1 mRNA (28, 32). These assays differ methodologically and so we directly

14 - Paul III, markanista kanademik (h. 1440).
14 - Johann Barnett, markanista kanademik (h. 1440).

322

323

324 **Discussion**

335 We used samples from opioid users to identify the phenomenon of LRA boosting: 336 improving the potency of HDACi beyond that of PMA-ionomycin by combining with a $2nd$ drug 337 that does not, by itself, re-activate HIV-1 transcription. This boosting occurred at lower LRA concentrations, here at least half the RMD, $1/10^{th}$ the bryostatin, and $1/100$ th the Smac mimetic 339 concentrations used in prior combination studies (28-31). Synergistic latency reversal effects of 340 low-dose bryostatin (1nM) and romidepsin was previously identified in samples from four 341 participants with HIV (28). Here we leveraged samples from forty-seven participants to confirm 342 those findings, extend the observation to HDACi in combination with low-dose bryostatin more 343 generally, and to LRA boosting with a Smac mimetic. A recent study identified that injection 344 opioid use was associated with a lack of ex vivo HIV-1 activation to TCR agonism (47). and our 345 findings in the subgroup of active injection opioid users agree with this. However, this 346 observation did not extend to other types of opioid use, e.g. suboxone use. Additional studies are

16 - Personal Personal de Personal de la Personal
16 - Personal de la Personal de la

349 While AZD5582 has been reported to induce virus transcription, we observed no HIV-1 350 latency reversal activity when used as a single agent in PBMC isolated from the 47 participants 351 we tested. AZD5582 monotherapy has been assessed for human ex vivo HIV-1 latency reversal 352 activity in four prior studies, using the endpoints of a quantitative virus outgrowth assay, HIV-1 353 cell-associated RNA levels, and HIV-1 p24 production. In these studies, QVOA and p24 354 responses were not observed in the majority of participants, HIV-1 *gag* caRNA increases were 355 approximately 2-fold, and the statistical significance of the results was less clear (53, 65, 66). 356 Our findings agree more with a recent study that assessed AZD5582 monotherapy and did not 357 identify HIV-1 LRA activity (32).

358 Our relatively large sample size, for this field, allowed us to determine that LRA boosting 359 was less likely to be affected by sex, race, or ethnicity. We do note, however, that non-opioid 360 participants in both our OPHION and HEAL cohorts were more likely to be black, whereas 361 participants who used opioids were a more racially and ethnically mixed population. The use of 362 two HDACi in our panel of ten LRA conditions increased the generalizability of the findings we 363 observed with this drug class. Similar magnitudes of boosting were observed with RMD and 364 PNB and suggests that class I histone deacetylase inhibition may be more relevant to this 365 phenomenon (67, 68). HDACi-induced changes in acetylated histone (AcH) H3 and/or H4 are 366 nearly exclusively reported in the literature as changes in MFI (13, 16-19, 69-72), not as a 367 function of the percent AcH-positive cells (16). To increase transparency, we report histone 368 acetylation changes both as the proportion of AcH-positive cells and by MFI; the 3-4-fold MFI 369 increases we report with RMD and PNB are consistent with prior literature*.* LRA boosting

17 - Andrew March, amerikansk politiker
17 - Johann Sterlin, amerikansk politiker
17 - Johann Sterlin, amerikansk politiker

 370 correlated with increased histone H3 acetylation in CD4⁺ T cells but AZD-associated boosting 371 did not recruit additional CD4s with acetylated histone H3. HDACi monotherapy also did not 372 increase the proportions of acetylated histone H3-positive CD4s and the amount of acetylated 373 histone H3 per cell did not meaningfully correlate with the induction of HIV-1 transcription. It 374 remains unclear if histone acetylation is correlative or causative to virus reactivation. In the 375 context of cellular genes, histone acetylation is not an immediate driver of the transcriptional 376 changes observed with HDACi (73). Similar magnitudes of HIV-1 reactivation were observed 377 with low-dose bryostatin and AZD5582-mediated HDACi boosting and could share common 378 mechanisms. Bryostatin and AZD5582 can activate canonical and non-canonical NF-κ^B 379 pathways, respectively, and the overlap in signaling with LRA boosting requires further 380 definition. A recent study performed an AZD5582-stimulated CRISPR screen and identified 381 HDAC2 as a potential synergistic drug target (32).

382 We identify that HIV-1 latency during treated virologically suppressed infection in PWH 383 is best described a period of inefficient, but not absent, virus mRNA production in blood. Real-384 time PCR assays that quantify HIV-1 persistence markers are not necessarily standardized across 385 research groups; the fold-change in HIV-1 unspliced caRNA levels that we observed with PMA-386 ionomycin stimulation were an order of magnitude lower than some prior studies which 387 quantified polyadenylated HIV-1 mRNA (28, 32). Our findings suggest this is not a result of 388 assay technical performance. Rather, qPCR assays of HIV-1 unspliced and poly(A) caRNA 189 levels may capture distinct biology, as a function of $CD4^+$ T cell phenotype. First, we identified 390 tCD4 contain more polyadenylated HIV-1 message than rCD4 in PWH. Second, PMAi 391 stimulation has more pronounced effects on the induction of HIV-1 poly(A) mRNA levels, 392 relative to unspliced RNA, and explains the discrepancy in PMAi-induced HIV-1 caRNA fold-

18 - Paul III, markanista kanademik (h. 1888).
18 - Johann Barnett, markanista kanademik (h. 1881).

1990 - Paul Bernard, Amerikaansk politiker
1990 - Paul Bernard, Amerikaansk politiker
1990 - Paul Bernard, Amerikaansk politiker

426 between replicates, has implications for future studies. Small studies may be limited in their 427 capacity to accurately quantify this variability, which increases with LRA potency and has been 428 observed in other in vitro and ex vivo work (79-81). We speculate this variability may relate to 429 heterogeneity in the HIV-1 reservoir, less so in the absolute amounts of provirus that may be 430 found in a given PBMC aliquot and more so to the capacity of a given set of proviruses, in their 431 unique intracellular environments, to support the reactivation of virus transcription. Assessments 432 of LRA activity should prioritize larger sample sizes and more than one biological replicate per 433 participant. We found that normalization of HIV-1 transcription to host gene transcription may 434 introduce additional variability. Despite HIV-1 re-activation that was superior to PMA-435 ionomycin, multiply spliced HIV-1 transcription and virion production did not significantly 436 increase with RMD in combination with low-dose bryostatin. Blocks to HIV-1 splicing are 437 increasingly recognized, and here we extend those findings to novel LRA boosting combinations 438 (23-25, 82-84). PMAi did not induce supernatant viremia, after a 24-hour incubation, in all

439 participants; this heterogeneity has been previously reported (85). In CD4⁺ T cell samples from a 440 subset of participants, however, we did observe detectable supernatant viremia but not increases 441 in the frequency of HIV-1 msRNA with the LRA boosting combination of romidepsin and low-442 dose bryostatin. It is possible that if an RNA splicing block limits LRA boosting-associated 443 virion production, it may not be absolute. Our study did not evaluate alternative possibilities that 444 virion production without significant HIV-1 msRNA increases may be due to virion production 445 kinetics, i.e. msRNA may be translated and degraded, may be due to the variance in LRA 446 response we document across experimental replicates, or may be due to assay technical 447 differences. Future work should focus on the post-transcriptional mechanisms of HIV-1 RNA 448 processing, and inter-patient differences in LRA responsiveness.

449 To standardize language, the term HIV-1 "latency reversal" may require more precise 450 wording. Latency reversal can refer to the reactivation of virus unspliced or poly(A) mRNA 451 transcription but can also be interpreted to mean the reversal of latency that results in viral 452 particle production. While some prior studies have identified HDACi-induced HIV-1 virion 453 production *ex vivo*, this required HDACi exposures over 6-14 days, at times in combination with 454 CD8 depletion or other LRA conditions that are more difficult to translate into investigational 455 strategies (70, 77, 79, 86).

456 Our study has limitations. Prior and current injection opioid use limits the peripheral 457 blood draw volumes we could obtain; this required us to prioritize the experiments we performed 458 with a given sample. The statistical significance of LRA boosting with AZD5582-containing 459 regimens was not replicated in our HEAL cohort samples and it is unclear if this relates to the 460 variability in LRA response as sample size decreases or to unrecognized differences between our 461 cohort's participants. We observed variance across clinical cohorts in the magnitude of LRA

21 - Animal Animal
2003 - Animal Anima

485 **Figure Legends**

486

500 **Figure 2.** HIV-1 latency reversal in OPHION participants. HIV-1 caRNA levels were quantified 501 after 24-hour incubations, in the presence of tenofovir 2 μM and raltegravir 2 μM, using 5 502 million PBMC and compared to a no-drug DMSO-containing condition. Mean values and the 503 95% CIs are shown. (a) Combined data showing LRA responses in thirty-six total participants 504 with (blue circles) or without (yellow circles) opioid use. Data from (a) was dichotomized by (b) 505 opioid use, (c) sex (light purple circles, male; light grey circles, female), and (d) race (light green 506 circles, Black and American Indian; dark green circles, white). Means and SEM are shown. 507 Dotted horizontal line denotes a fold-change of 1. *p<0.05, ** p<0.01, *** p<0.001, and ****

23

508 p<0.0001 for LRA combinations, corrected for multiple comparisons. αCD3/αCD28, anti-CD3 509 anti-CD28 superparamagnetic beads; RMD, romidepsin; PNB, panobinostat; R, RMD 20nM; P, 510 PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM.

511

512 **Figure 3.** Immune activation and cytokine induction during *ex vivo* LRA boosting. (a) Example 513 plots of OX40⁺PD-L1⁺, OX40⁺CD25⁺, and CD69⁺CD40L⁺ expression from gated live CD4⁺ T 514 cells in PBMC samples incubated with DMSO control or an αCD3/αCD28 bead positive control 515 for 18 hours, (b) Violin plots of surface activation-induced marker (AIM) response as a function 516 of LRA. Results across three highly sensitive AIM assays for OPHION participants' samples 517 (n=36) are shown for comparison, (c) Quantification of LRA-induced surface CD69 expression 18 in live total CD4⁺ T cells (n=36). Intracellular production of the cytokines TNF-α, IFN-γ, and IL-519 2 during LRA exposure in (d) live $CD4^+$ and (e) $CD8^+$ T cells (n=36). Violin plot median values 520 are indicated by a solid black line; quartiles are shown with a dotted line. LRA conditions 521 without visible bars represent values $< 0.1\%$ of cells. *p < 0.05 , *** p < 0.001 , and **** p < 0.0001 522 for LRA combinations, corrected for multiple comparisons. RMD, romidepsin; PNB, 523 panobinostat; R, RMD 20nM; P, PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM. 524

525 **Figure 4.** LRA boosting increases histone acetylation. (a) Violin plots showing the proportion of 526 gated live total $CD4^+$ T cells with acetylated histone H3, assessed by flow cytometry, (b) Violin plot of mean fluorescence intensity (MFI) of acetylated histone H3 per live $CD4^+$ T cell. Scatter 528 plots of acetylated histone H3 levels per CD4 as a function of HIV-1 transcription in response to 529 RMD and PNB monotherapy (c), LRA boosting with HDACi and AZD5582 (d), and HDACi in 530 combination with low-dose bryostatin (e) are shown. Acetylated histone levels and HIV-1

24 - Paul III, mark et al. 1990 et al.
24 - Paul III, mark et al. 1990 et al.

25 (25 April 2012). The contract of the contract of

577 **Materials and Methods**

578 **Study Design and Clinical Cohorts**

579 The Opioids, HIV, and Translation (OPHION) study is a prospective cohort study of participants 580 living with HIV on suppressive antiretroviral therapy recruited from Boston Medical Center 581 which serves one of the largest populations of people living with HIV (PLWH) in Massachusetts, 582 including a disproportionately large number of persons with opioid and substance use disorders. 583 Eligible PLWH were required to currently be on antiretroviral therapy and virologically 584 suppressed (defined as undetectable plasma HIV-1 RNA or <20 copies/ml) for a minimum of 12 585 months prior to enrollment. Individuals were recruited into 1 of 5 cohorts: (1) active injection 586 opioid use, defined as self-report on injecting opioids at least once per week, (2) Methadone 587 maintenance therapy for at least 3 months, (3) buprenorphine-naloxone therapy for at least 3 588 months, (4) Prescription oral opioid use for at least 6 months or (5) No opioid use within the past 589 1 year representing a control cohort. Eligibility into each of the five cohorts was confirmed with 590 a urine toxicology performed at the BMC central laboratory, which includes evaluation for urine 591 drug metabolites including opiates and non-opioid substances as well as an expanded opioid 592 panel which included fentanyl or norfentanyl metabolites. Exclusionary criteria included ongoing 593 immunosuppression and pregnancy; patients who reported injecting non-opioid substances were 594 also not eligible. Once consented and enrolled, each participant underwent blood collection for 595 same day PBMC extraction as well as urine collection for gabapentin and benzodiazepine 596 metabolites. Participants also completed an extensive survey on their current and prior substance 597 use (including alcohol and tobacco use) based the addiction severity index (ASI) (88) and Texas 598 Christian University (TCU) drug screen (89). HIV and other clinical information including ART

27 (27) 27 (27) 27 (27) 27 (27) 27 (27) 27 (27) 27 (27) 27 (27) 27 (27) 27 (27) 27 (27) 27 (27) 27 (27) 27 (27

599 treatment history, duration of virologic suppression and comorbidity status including hepatitis C 600 and B were abstracted from the medical record.

- 601 The HIV Eradication and Latency (HEAL) Cohort is a longitudinal biorepository study of 602 participants with HIV. Inclusion criteria for HEAL participants in this study were 1) 603 antiretroviral therapy-treated participants with HIV-1 who were virologically suppressed, defined 604 as plasma HIV-1 RNA less than assay (most commonly less than 20 copies/mL, without blips) 605 for >1 year and 2) had sufficient available amounts of cryopreserved PBMC for the proposed 606 analyses. These cohort studies are performed in accordance with the principles of the Declaration 607 of Helsinki. The institutional review boards at Boston Medical Center and Brigham and 608 Women's Hospital (Mass General Brigham Human Research Committee) approved the study 609 protocols. Written informed consent was obtained from all participants. Experimenters were 610 blinded to all clinical data and to OPHION subgroup assignments.
- 611

612 **Quantification of HIV-1 persistence markers**

613 Genomic DNA and total RNA were isolated from approximately $5x10^6$ peripheral blood 614 mononuclear cells (PBMC) or total $CD4^+$ T cells (AllPrep DNA/RNA kit, Qiagen). Total HIV-1 615 DNA and unspliced cell-associated RNA (caRNA) levels were quantified in triplicate by real-616 time PCR as previously described, modified to include Taqman Universal Mastermix (DNA) or 617 Taqman Fast Virus 1-Step Mastermix (RNA) (90). HIV-1 quantifications used forward primer 618 5'-TACTGACGCTCTCGCACC-3', reverse primer 5'-TCTCGACGCAGGACTCG-3', and 619 probe 5' FAM-CTCTCTCCTTCTAGCCTC-MGB 3' (ThermoFisher Scientific). DNA cycling 620 conditions in a total reaction volume of 25μ L were 95°C for 15 min followed by 40 cycles of 621 95 °C for 15 sec and 60 °C for 1 min. RNA cycling conditions in a total reaction volume of $20\mu L$

28

- 645 for sheared DNA, separate reactions targeting two regions of the *RPP30* gene, RPP30-1
- 646 (Forward: 5'-GATTTGGACCTGCGAGCG-3'; Reverse: 5'-GCGGCTGTCTCCACAAGT-3';
- 647 Probe: 5'-CTGACCTGAAGGCTCT-3', VIC/HEX, MGB) and RPP30-2 (Forward: 5'-
- 648 GACACAATGTTTGGTACATGGTTAA-3'; Reverse: 5'-
- 649 CTTTGCTTTGTATGTTGGCAGAAA-3'; Probe: 5'-
- 650 CCATCTCACCAATCATTCTCCTTCCTTC -3', VIC/HEX), with similar nucleotide distance

651 between targets compared to *Psi* and *env* were prepared with 70 ng DNA per well. Droplets were

- 652 generated and subjected to PCR cycle: 95° C for 10 minutes, followed by 45 cycles of 94° C for
- 653 30 seconds, 59°C for 1 minute, and ending with 98°C for 10 minutes before holding at 4°C. Data
- 654 from PCR products were collected and analyzed using QuantaSoft Data Analysis Software.
- 655 Droplets containing a double positive signal (*Psi*+/*env*+) were considered intact, while single
- 656 positive droplets represented defective provirus containing 5' deletions (*Psi*-/*env*+) or 3'
- 657 deletions/hypermutations (*Psi*+/*env*-). Relative DNA shearing was calculated using the ratio of
- 658 single positive RPP30 droplets compared to the double positive population and was used to
- 659 estimate the number of intact proviruses. The number of diploid cells in each reaction was
- 660 determined by dividing the copies of RPP30 in half and correcting for the dilution factor for the
- 661 HIV-1 reaction. Intact, defective, and total HIV-1 DNA were normalized to the number of cells
- 662 and reported as copies/million PBMC.
- 663

664 **Multiply spliced HIV-1 transcripts**

665 To measure the frequency of total $CD4^+$ T cells with inducible multiply spliced HIV-1 RNA, we 666 performed the TILDA assay, as previously described, with two modifications (56). First, to 667 reduce the 95% CIs around our frequency estimates, we used 36 x 10^6 cells/mL as our first

300 and 300 an
300 and 300 an

31 - San Angeles II (1918) - San Angel

691 synthesized using T3 Megascript Kit (ThermoFisher Cat. No. AM1333 and cleaned (RNease 692 MinElute Cleanup Kit, Qiagen, Cat. No. 74204) before serially diluting across a range of 10^6 – 693 10^3 copies per well. After TBP and UBE2D2 standards were individually validated, TBP (T) 694 and UBE2D2 (U) RNA were diluted separately and aliquoted together as one set of multiplex 695 standards. T and U standards were validated to demonstrate overlap of individual and 696 multiplexed standards curves. The assay was optimized to run all host gene standards and 697 samples on one 96-well reaction plate in a total reaction volume of 20µL using cycling 698 conditions of 55° C for 5 min, 95° C for 20 sec, followed by 40 cycles of 95° C for 3 sec and 56° C 699 for 30 sec. Reference gene standards and samples were run in duplicate. IPO8, TBP, and 700 UBE2D2 RNA copies per million PBMC were calculated by dividing copies per total sample by 701 number of cells per sample, determined by CCR5 quantification, and normalized to $1x10^6$ cells. 702 Fold changes were calculated by dividing the RNA copy number obtained per million PBMC for 703 each LRA condition by the 0.2% DMSO control condition's reference gene RNA copies/million 704 PBMC.

705

706 **HIV-1 latency reversal**

707 OPHION and HEAL participant peripheral blood mononuclear cells (PBMC) were isolated from 708 large volume (90 – 180cc) peripheral blood or leukapheresis collections by density centrifugation 709 and cryopreserved. Cryopreserved PBMC were thawed, pelleted, and transferred to RPMI media 710 supplemented with 10% fetal bovine serum, 2 μ M raltegravir, and 2 μ M tenofovir (R10 + TDF/RAL) at a concentration of $1x10^6$ cells/mL. Cells were rested in a humidified CO₂ 712 incubator at 37°C for three hours (hrs). After 3hrs, cells were counted and assessed for viability. 713 For CD4⁺ T cell experiments, PBMC were pelleted, resuspended in EasySep Buffer (StemCell

729 **Comparison of qPCR assays after reactivation**

730 CD4⁺ T cells were isolated from cryopreserved HEAL participant PBMCs. Total CD4s (tCD4)

731 were isolated using a CD3+CD4+CD8- isolation kit (StemCell cat. no. 17952) and resting CD4s

732 (rCD4) were isolated using a CD3+CD4+CD8-CD25-CD69-HLA-DR- isolation kit (StemCell

733 cat. no. 17962). Cells were pelleted and transferred to RPMI media supplemented with 10% fetal

734 bovine serum, 2 μM raltegravir, and 2 μM tenofovir $(R10 + TDF/RAL)$ at a concentration of

735 5×10^6 cells/mL. Cells were rested in a humidified CO₂ incubator at 37°C for 3h and then counted

736 and assessed for viability. A total of 5×10^6 tCD4s or rCD4⁺ T cells were aliquoted into either

737 1mL or 5mL of fresh R10 + RAL/TDF in a 24-well sterile cell culture plate or 6-well sterile cell 738 culture plate, respectively. Cells were incubated in either 0.2% DMSO or phorbol 12-myristate 739 13-acetate (PMA) 50ng/mL (Sigma, cat. no. P1585) in combination with ionomycin 1μ^M 740 (Sigma, cat. no. I9657). Cultures were incubated at 37°C for 24 hours. After 24 hours, cells were 741 prepared for nucleic acid extractions. RNA was eluted in a total volume of 65uL and DNA eluted 742 in a volume of 100uL. For HIV-1 unspliced caRNA quantifications, 10uL of RNA were assessed 743 in triplicate using primers and probe that bind the HIV-1 *gag* region (90). To calculate copies of 744 HIV-1 caRNA per million cells, copy numbers were averaged and cell counts normalized to a 745 CCR5 DNA reference. For polyadenylated HIV-1 mRNA quantifications, 10uL (approximately 746 1 million cell equivalents) of RNA were run in triplicate using primers and probe targeting the 747 nef to poly-A region of HIV-1 mRNA as previously described (28). Our HIV-1 unspliced and 748 poly(A) caRNA amplifications are both one-step qPCR assays that use an HIV-specific primer to 749 synthesize cDNA. Standards were generated as previously described (92). For poly(A) HIV-1 750 mRNA quantifications, copies per million cell equivalents were calculated by initial cell count 751 prior to reactivation. Both assays used Taqman Fast Virus 1-Step Mastermix in a total reaction 752 volume of 20μL and cycling conditions of 55°C for 15 min, 95°C for 20 sec, followed by 40 753 cycles of 95°C for 3 sec and 60°C for 30 sec. Fold-change was calculated by dividing copies per 754 million cells in the PMAi condition by copies per million cells in the 0.2% DMSO no drug 755 control condition for each sample.

756

757 **Activation Induced Marker (AIM) assay**

758 AIM assays were performed as previously described (54). Briefly, cryopreserved PBMC were 759 thawed, washed, resuspended in R10, and rested for 3 hours at 37°C. Following the 3-hour rest

and the state of th
State of the state of the state

774

775 **Intracellular cytokine staining**

776 Cryopreserved PBMC were thawed, washed, resuspended in RPMI + 10% FBS (R10), and 777 rested for 3 hours at 37°C. Following the 3-hour rest interval, the appropriate number of cells 778 were transferred to a 48-well plate and incubated for 2 hrs with our panel of 10 LRA. Following 779 this 2-hour incubation period, GolgiPlug (BD, cat. no. 555029) and GolgiStop (BD, cat. no. 780 554724) were added to each condition at a concentration of 1:1000 and 6:10000 respectively, 781 then incubated at 37°C for an additional 16 hrs. Cells were harvested, pelleted, resuspended, 782 stained for 20 minutes at 4°C with surface staining mAb (CD3-BV605, CD4-BV421, CD8-

35 September 2005 Se

794 **Statistical analysis**

795 Statistical analyses were performed using GraphPad Prism 9 for macOS. Means, medians, 95% 796 confidence intervals, and standard errors of the mean were calculated. The pre-specified primary 797 outcome of OPHION was a comparison of log_{10} PBMC HIV-1 caRNA levels between 798 participants who use and do not use opioids. The pre-specified outcome for OPHION latency 799 reversal experiments was the difference in HIV-1 caRNA levels between LRA treatment groups 800 and across opioid use groups. To assess for changes in HIV-1 caRNA, we performed Kruskal-801 Wallis testing of all participants together for each of the LRAs with Dunn's multiple comparison 802 test, comparing the mean ranks of LRA conditions. An identical approach was taken with a 803 series of exploratory analyses with OPHION participant samples that assessed histone 804 acetylation, surface activation, and intracellular cytokine production, and with the exploratory

807

808 **Acknowledgements**

- 809 This work is supported by the National Institutes of Health (NIH) R61 DA047038 (NL and AT)
- 810 and R33 DA047038 (AT) and was facilitated by the Providence/Boston Center for AIDS
- 811 Research (P30AI042853) and the Harvard University Center for AIDS Research (P30AI060354).
- 812 The project described was further supported by Clinical Translational Science Award
- 813 1UL1TR002541-01 to Harvard University and Brigham and Women's Hospital from the
- 814 National Center for Research Resources. The content is solely the responsibility of the authors
- 815 and does not necessarily represent the official views of the National Center for Research

816 Resources or the National Institutes of Health.

817

818 **Author contributions:**

851 **References**

39 September 2008 September 2009 September 2009

- 873 8. Mullins JI, Frenkel LM. Clonal Expansion of Human Immunodeficiency Virus-Infected
- 874 Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy. The
- 875 Journal of infectious diseases. 2017;215(suppl_3):S119-S27.
- 876 9. Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, et al.
- 877 International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature
- 878 medicine. 2016.
- 879 10. Ferrari G, Pollara J, Tomaras GD, Haynes BF. Humoral and Innate Antiviral Immunity as
- 880 Tools to Clear Persistent HIV Infection. The Journal of infectious diseases.
- 881 2017;215(suppl_3):S152-S9.
- 882 11. Riley JL, Montaner LJ. Cell-Mediated Immunity to Target the Persistent Human
- 883 Immunodeficiency Virus Reservoir. The Journal of infectious diseases. 2017;215(suppl_3):S160- 884 S71.
- 885 12. McMahon DK, Zheng L, Cyktor JC, Aga E, Macatangay BJ, Godfrey C, et al. A Phase
- 886 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on
- 887 Suppressive Antiretroviral Therapy. The Journal of infectious diseases. 2021;224(4):648-56.
- 888 13. Scully EP, Aga E, Tsibris A, Archin N, Starr K, Ma Q, et al. Impact of Tamoxifen on
- 889 Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral
- 890 Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. Clin Infect Dis.
- 891 2022;75(8):1389-96.
- 892 14. Gutierrez C, Serrano-Villar S, Madrid-Elena N, Perez-Elias MJ, Martin ME, Barbas C, et
- 893 al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy.
- 894 AIDS (London, England). 2016;30(9):1385-92.

400 - Animal Alexandria de Alexandria de Alexandria de Alexandria de Alexandria de Alexandria de Alexandria d
1904 - Animal Alexandria de Alexandria de Alexandria de Alexandria de Alexandria de Alexandria de Alexandria

- 895 15. Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, et al. HIV-1
- 896 expression within resting CD4+ T cells after multiple doses of vorinostat. The Journal of
- 897 infectious diseases. 2014;210(5):728-35.
- 898 16. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al.

899 Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 900 2012;487(7408):482-5.

901 17. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, et al. Activation

902 of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive

903 antiretroviral therapy. PLoS pathogens. 2014;10(10):e1004473.

904 18. Sogaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, et al. The

905 Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS pathogens.

906 2015;11(9):e1005142.

907 19. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al.

908 Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected

909 patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. The lancet

910 HIV. 2014;1(1):e13-21.

911 20. Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, et al. Valproic acid 912 in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: 913 results from a multicentre randomized clinical study. HIV medicine. 2012;13(5):291-6.

914 21. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, et al.

915 Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS

916 (London, England). 2008;22(10):1125-9.

41 - Animal Animal
Animal Animal Anima

- 917 22. Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, et al. Interval dosing
- 918 with the HDAC inhibitor vorinostat effectively reverses HIV latency. The Journal of clinical
- 919 investigation. 2017;127(8):3126-35.
- 920 23. Yukl SA, Kaiser P, Kim P, Telwatte S, Joshi SK, Vu M, et al. HIV latency in isolated
- 921 patient $CD4(+)$ T cells may be due to blocks in HIV transcriptional elongation, completion, and
- 922 splicing. Science translational medicine. 2018;10(430).
- 923 24. Moron-Lopez S, Kim P, Sogaard OS, Tolstrup M, Wong JK, Yukl SA. Characterization
- 924 of the HIV-1 transcription profile after romidepsin administration in ART-suppressed
- 925 individuals. AIDS (London, England). 2019;33(3):425-31.
- 926 25. Zerbato JM, Khoury G, Zhao W, Gartner MJ, Pascoe RD, Rhodes A, et al. Multiply
- 927 spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following
- 928 reversal of HIV latency. EBioMedicine. 2021;65:103241.
- 929 26. Martin HA, Kadiyala GN, Telwatte S, Wedrychowski A, Chen TH, Moron-Lopez S, et
- 930 al. New Assay Reveals Vast Excess of Defective over Intact HIV-1 Transcripts in Antiretroviral
- 931 Therapy-Suppressed Individuals. Journal of virology. 2022;96(24):e0160522.
- 932 27. Rodari A, Darcis G, Van Lint CM. The Current Status of Latency Reversing Agents for
- 933 HIV-1 Remission. Annu Rev Virol. 2021;8(1):491-514.
- 934 28. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, et al. Ex vivo 935 analysis identifies effective HIV-1 latency-reversing drug combinations. The Journal of clinical 936 investigation. 2015;125(5):1901-12.
- 937 29. Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, et al. BIRC2/cIAP1 Is
- 938 a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to
- 939 Promote Reversal of Viral Latency. Cell host & microbe. 2015;18(3):345-53.

- 940 30. Grau-Exposito J, Luque-Ballesteros L, Navarro J, Curran A, Burgos J, Ribera E, et al.
- 941 Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T
- 942 subpopulations. PLoS pathogens. 2019;15(8):e1007991.
- 943 31. Pardons M, Fromentin R, Pagliuzza A, Routy JP, Chomont N. Latency-Reversing Agents
- 944 Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on
- 945 Antiretroviral Therapy. Cell Rep. 2019;29(9):2783-95 e5.
- 946 32. Dai W, Wu F, McMyn N, Song B, Walker-Sperling VE, Varriale J, et al. Genome-wide
- 947 CRISPR screens identify combinations of candidate latency reversing agents for targeting the
- 948 latent HIV-1 reservoir. Science translational medicine. 2022;14(667):eabh3351.
- 949 33. Gupta V, Dixit NM. Trade-off between synergy and efficacy in combinations of HIV-1 950 latency-reversing agents. PLoS computational biology. 2018;14(2):e1006004.
- 951 34. Kao SY, Calman AF, Luciw PA, Peterlin BM. Anti-termination of transcription within
- 952 the long terminal repeat of HIV-1 by tat gene product. Nature. 1987;330(6147):489-93.
- 953 35. Adams M, Sharmeen L, Kimpton J, Romeo JM, Garcia JV, Peterlin BM, et al. Cellular
- 954 latency in human immunodeficiency virus-infected individuals with high CD4 levels can be
- 955 detected by the presence of promoter-proximal transcripts. Proceedings of the National Academy
- 956 of Sciences of the United States of America. 1994;91(9):3862-6.
- 957 36. Lassen KG, Bailey JR, Siliciano RF. Analysis of human immunodeficiency virus type 1 958 transcriptional elongation in resting CD4+ T cells in vivo. Journal of virology.
- 959 2004;78(17):9105-14.
- 960 37. Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, et al.
- 961 Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of
- 962 inflammation or activation. PLoS pathogens. 2017;13(4):e1006285.

982 Pharmacol. 2008;74(2):496-504.

983 45. Borner C, Warnick B, Smida M, Hartig R, Lindquist JA, Schraven B, et al. Mechanisms

984 of opioid-mediated inhibition of human T cell receptor signaling. J Immunol. 2009;183(2):882-9.

44 - Anima Alexandria, Anima alemaniar alemaniar alemaniar alemaniar alemaniar alemaniar alemaniar alemaniar a
Alexandria

45 Million and the control of the c

- 1008 54. Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, et al. Comparative
- 1009 analysis of activation induced marker (AIM) assays for sensitive identification of antigen-
- 1010 specific CD4 T cells. PLoS ONE. 2017;12(10):e0186998.
- 1011 55. Ceriani C, Streeter GS, Lemu KJ, James KS, Ghofrani S, Allard B, et al. Defining stable
- 1012 reference genes in HIV latency reversal experiments. Journal of virology. 2021;95(11).
- 1013 56. Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, et al. A Novel
- 1014 Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals.
- 1015 EBioMedicine. 2015;2(8):874-83.
- 1016 57. Mehandru S, Deren S, Kang SY, Banfield A, Garg A, Garmon D, et al. Behavioural,
- 1017 Mucosal and Systemic Immune Parameters in HIV-infected and Uninfected Injection Drug
- 1018 Users. J Addict Res Ther. 2015;6(4):1-8.
- 1019 58. Deren S, Cleland CM, Lee H, Mehandru S, Markowitz M. Brief Report: The Relationship
- 1020 Between Injection Drug Use Risk Behaviors and Markers of Immune Activation. Journal of
- 1021 acquired immune deficiency syndromes (1999). 2017;75(1):e8-e12.
- 1022 59. Khoury G, Fromentin R, Solomon A, Hartogensis W, Killian M, Hoh R, et al. Human
- 1023 Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node
- 1024 Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive
- 1025 Antiretroviral Therapy. The Journal of infectious diseases. 2017;215(6):911-9.
- 1026 60. Massanella M, Fromentin R, Chomont N. Residual inflammation and viral reservoirs:
- 1027 alliance against an HIV cure. Current opinion in HIV and AIDS. 2016;11(2):234-41.
- 1028 61. Ruggiero A, De Spiegelaere W, Cozzi-Lepri A, Kiselinova M, Pollakis G, Beloukas A, et
- 1029 al. During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral

1030 Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ.

- 1031 EBioMedicine. 2015;2(9):1153-9.
- 1032 62. Cockerham LR, Siliciano JD, Sinclair E, O'Doherty U, Palmer S, Yukl SA, et al. CD4+
- 1033 and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells. PLoS ONE.

1034 2014;9(10):e110731.

- 1035 63. Kirk GD, Astemborski J, Mehta SH, Ritter KD, Laird GM, Bordi R, et al. Nonstructured
- 1036 Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir

1037 Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs. The Journal of

- 1038 infectious diseases. 2021;223(11):1905-13.
- 1039 64. Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, et al.
- 1040 Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nat
- 1041 Commun. 2019;10(1):3193.
- 1042 65. Falcinelli SD, Peterson JJ, Turner AW, Irlbeck D, Read J, Raines SL, et al. Combined

1043 noncanonical NF-kappaB agonism and targeted BET bromodomain inhibition reverse HIV

- 1044 latency ex vivo. The Journal of clinical investigation. 2022;132(8).
- 1045 66. Li D, Dewey MG, Wang L, Falcinelli SD, Wong LM, Tang Y, et al. Crotonylation
- 1046 sensitizes IAPi-induced disruption of latent HIV by enhancing p100 cleavage into p52. iScience.

1047 2022;25(1):103649.

- 1048 67. Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, et al. Histone
- 1049 Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and
- 1050 Pharmacological Actionability. Genes (Basel). 2020;11(5).

- 1051 68. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. Expression of
- 1052 latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase
- 1053 inhibitors. AIDS (London, England). 2009;23(14):1799-806.
- 1054 69. Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V. Ex Vivo Bioactivity
- 1055 and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells
- 1056 from Aviremic Patients. Antimicrobial agents and chemotherapy. 2015;59(10):5984-91.
- 1057 70. Banga R, Procopio FA, Cavassini M, Perreau M. In Vitro Reactivation of Replication-
- 1058 Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors. Journal of virology.
- 1059 2016;90(4):1858-71.
- 1060 71. Tsai P, Wu G, Baker CE, Thayer WO, Spagnuolo RA, Sanchez R, et al. In vivo analysis
- 1061 of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV
- 1062 infection. Retrovirology. 2016;13(1):36.
- 1063 72. Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM. Histone deacetylase inhibitors
- 1064 (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory
- 1065 complex also activate HIV transcription. The Journal of biological chemistry.
- 1066 2013;288(20):14400-7.
- 1067 73. Halsall JA, Turan N, Wiersma M, Turner BM. Cells adapt to the epigenomic disruption
- 1068 caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated
- 1069 transcriptional response. Epigenetics Chromatin. 2015;8:29.
- 1070 74. Chen FX, Smith ER, Shilatifard A. Born to run: control of transcription elongation by
- 1071 RNA polymerase II. Nat Rev Mol Cell Biol. 2018;19(7):464-78.

- 1073 activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and
- 1074 "kill" in strategy for virus eradication. PLoS pathogens. 2017;13(9):e1006575.
- 1075 76. Spivak AM, Nell RA, Petersen M, Martins L, Sebahar P, Looper RE, et al. Synthetic
- 1076 Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal. Antimicrobial agents
- 1077 and chemotherapy. 2018;62(11).
- 1078 77. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, et al. Histone
- 1079 Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on
- 1080 Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing. PLoS
- 1081 pathogens. 2014;10(4):e1004071.
- 1082 78. Walker-Sperling VE, Pohlmeyer CW, Tarwater PM, Blankson JN. The Effect of Latency
- 1083 Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for
- 1084 Human Immunodeficiency Virus Eradication. EBioMedicine. 2016;8:217-29.
- 1085 79. Bouchat S, Delacourt N, Kula A, Darcis G, Van Driessche B, Corazza F, et al. Sequential
- 1086 treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1. EMBO Mol
- 1087 Med. 2016;8(2):117-38.
- 1088 80. Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, et al. An In-Depth
- 1089 Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1
- 1090 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral
- 1091 Gene Expression. PLoS pathogens. 2015;11(7):e1005063.
- 1092 81. Bui JK, Mellors JW, Cillo AR. HIV-1 Virion Production from Single Inducible
- 1093 Proviruses following T-Cell Activation Ex Vivo. Journal of virology. 2016;90(3):1673-6.

- 1094 82. Wedrychowski A, Martin HA, Li Y, Telwatte S, Kadiyala GN, Melberg M, et al.
- 1095 Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control. Journal
- 1096 of virology. 2023;97(1):e0125422.
- 1097 83. Moron-Lopez S, Telwatte S, Sarabia I, Battivelli E, Montano M, Macedo AB, et al.
- 1098 Human splice factors contribute to latent HIV infection in primary cell models and blood CD4+
- 1099 T cells from ART-treated individuals. PLoS pathogens. 2020;16(11):e1009060.
- 1100 84. Mota TM, McCann CD, Danesh A, Huang SH, Magat DB, Ren Y, et al. Integrated
- 1101 Assessment of Viral Transcription, Antigen Presentation, and CD8(+) T Cell Function Reveals
- 1102 Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency
- 1103 Reversal. Journal of virology. 2020;94(9).
- 1104 85. Walker-Sperling VE, Cohen VJ, Tarwater PM, Blankson JN. Reactivation Kinetics of
- 1105 HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific
- 1106 CD8+ T Cells. Journal of virology. 2015;89(18):9631-8.
- 1107 86. Kula A, Delacourt N, Bouchat S, Darcis G, Avettand-Fenoel V, Verdikt R, et al.
- 1108 Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined
- 1109 Disulfiram+Romidepsin Treatments. Journal of acquired immune deficiency syndromes (1999). 1110 2019;80(5):605-13.
- 1111 87. Mbonye U, Leskov K, Shukla M, Valadkhan S, Karn J. Biogenesis of P-TEFb in CD4+ T
- 1112 cells to reverse HIV latency is mediated by protein kinase C (PKC)-independent signaling
- 1113 pathways. PLoS pathogens. 2021;17(9):e1009581.
- 1114 88. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The Fifth
- 1115 Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199-213.

1118 drug-screen/ [

- 1119 90. Malnati MS, Scarlatti G, Gatto F, Salvatori F, Cassina G, Rutigliano T, et al. A universal
- 1120 real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nature protocols.

1121 2008;3(7):1240-8.

- 1122 91. Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, et al. A
- 1123 quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature.

1124 2019;566(7742):120-5.

1125 92. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches

1126 distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nature

1127 medicine. 2014;20(4):425-9.

- 1128
- 1129
- 1130
- 1131
- 1132
- 1133
-
- 1134
- 1135
- 1136

1137

1138

1139 **Supplementary Figures Legends**

1140 **Supplementary Figure 1.** Substance use in the OPHION cohort. We assessed substance 1141 use by (a) clinical urine toxicology testing and (b) self-reported substance use questionnaires. 1142 Substance use results are separated by cohort groups by participant ID. Red squares indicate the 1143 presence of that substance in a urine sample; unavailable data were marked with "X" in a gray 1144 box. An expanded opiate panel was performed to assess for the presence of different opiate 1145 formulations. Color squares in panel b reflect any reported use by participants in the last 30 days. 1146 The numbers inside a given box indicate the number of days used this substance was reported to 1147 be used in the last 30 days. Gradient of color from blue to red indicate increasing report of use 1148 whereas white indicates no use. Concomitant use of alcohol, tobacco, marijuana, and gabapentin 1149 in the OPHION cohort was common. *all fentanyl measures were confirmed by follow-on 1150 quantification. Participants in the buprenorphine and methadone groups reported daily use of the 1151 respective medication in the 30 days prior, whereas participants taking opioids for chronic pain 1152 took opioids for 27-30 days in the 30 days preceding their enrollment in OPHION. 75% (N=3/4) 1153 of active injection users had urine toxicology screens positive for cocaine corresponding with 1154 self-report; all three reported smoking cocaine in the prior 30 days to specimen collection. One 1155 of twelve participants in the methadone use group and 2/12 in the non-opiate use group also has 1156 urine toxicology screens positive for cocaine. All active injection opioid users reported using 1157 multiple drugs on the same day in the last 30 days compared to 1/12 participants in non-opioid 1158 use group and 10/20 participants in methadone, buprenorphine and prescription opiate use 1159 groups combined. N=3/4 active injection opioid users reported smoking marijuana in the last 30 1160 days. 6 and 8 participants about the 12 participants in opioid use groups had urine toxicology 1161 screens positive for benzodiazepines and gabapentin; all but 1 in both cases reported that this

52

53

1184 obtained with the (a) OX40/PD-L1, (b) OX40/CD25, and (c) CD69/CD40L AIM assays are

1196 **Supplementary Figure 5.** Histone acetylation effects during LRA boosting, as a function of 1197 opioid use. Using the same data displayed in Main Fig. 4, here we show individual data points, 1198 labelled as samples from participants with (blue circles) and without (yellow circles) opioid use. (a) The proportion of live total $CD4^+$ T cells with acetylated histone H3, assessed by flow 1200 cytometry, (b) Mean fluorescence intensity (MFI) of acetylated histone H3 per live total CD4⁺ T 1201 cells.

1202

1203 **Supplementary Figure 6.** The effects of LRA boosting on human reference gene transcription. 1204 Using leukapheresis samples from HEAL participants (n=10), we assessed and compared fold-1205 changes in transcription of three host genes: (a) IPO8, (b) TBP, and (c) UBE2D2. Reference 1206 gene multiplexing was validated for (d) TBP and (e) UBE2D2 quantifications. The rationale to 1207 study these three reference genes is as follows. IPO8 transcription is used as an internal control

54

1226

1227 **Supplementary Figure 8.** Variance in LRA response. (a) Magnitude of HIV-1 caRNA

1228 transcription fold-changes in biological replicate LRA experiments performed with HEAL

- 1229 leukapheresis samples, using the same data as shown in Main Fig 5a-c, (b) Box and whiskers
- 1230 plot displaying the data of Fig. 5g as the mean (solid black horizontal line), inter-quartile range

555 - San Angeles II (1955 - San Angeles
1955 - San Angeles II (1955 - San Angeles

- (25th 75th percentiles denoted as the borders of the vertical rectangle), and 5^{th} -95th percentiles
- 1232 (whiskers, error bars). Values below and above the whiskers are shown as individual data points.
- 1233 PMA-iono, PMA with ionomycin; RMD, romidepsin; PNB, panobinostat; R, RMD 20nM; P,
- 1234 PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM.
- 1235
- 1236 **Supplementary Tables**
- 1237 **Supplementary Table 1** Breakdown of OPHION cohort into opioid use subgroups
- 1238 **Supplementary Table 2** HEAL Participant Characteristics
- 1239
- 1240

a.

- Intact \bullet
- 3' deletion/hypermut
- 5' deletion \bullet

c.

Opioid injection Oral opioid Methadone Suboxone No drug

0

100

200

0.0

 $0.2 -$

0

0 20 40 60 80 100 P+A R+A P+B R+B $AZD5582$ PNB RMD^O Bryostatin α CD3/ α CD28 Untreated \blacktriangleright % CD69+ Cells of Total CD4+ T Cells **

Figure 4

*

 \bigcirc

 \bigcirc

e.

